anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain an antiviral agent containing a nucleoside containing a new compound and salt thereof, having activity to a human immunodeficiency virus(HIV) and useful in remedy for AIDS. CONSTITUTION:The antiviral agent containing a compound expressed by the formula (B is thymin-1-yl, cytosin-1-yl, etc., and R&lt;1&gt; is amino or B is thymin-1-yl or adenin-9-yl and R&lt;1&gt; is -N=CH2, etc.) and salt thereof (e.g. hydrochloride, sulfate or phosphate). The compound expressed by the formula is also useful in remedy for other disorders, e.g., asymptomatic carrier condition, progressive systemic lymph node disease and AIDS syndrome, accompanying to HIV infection. A compound expressed by the formula wherein B is thymin-1-yl or cytosin-1-yl and R&lt;1&gt; is a group other than amino is a new compound among the compound expressed by the formula.
PCT No. PCT/JP96/02494 Sec. 371 Date Mar. 4, 1998 Sec. 102(e) Date Mar. 4, 1998 PCT Filed Sep. 4, 1996 PCT Pub. No. WO97/09318 PCT Pub. Date Mar. 13, 1997The present invention is directed to a pyrimidine derivative of the following formula (1) or a salt of the derivative:    &lt;IMAGE&gt;  (1)  [wherein R1 represents a hydroxyl group, a lower alkoxy group, a phenyloxy group which may have a substituent, an aralkyloxy group which may have a substituent, or -NR2R3; X represents an oxygen atom or N-R4; m is 2 or 3; and n is 1 or 2 (wherein each of R2 and R3, which are identical to or different from each other, represents a hydrogen atom, a hydroxyl group, a lower alkyl group which may have a substituent, a phenyl group which may have a substituent, an aralkyl group which may have a substituent, or a heterocyclic group which may have a substituent; R4 represents a lower alkyl group, a phenyl group, a formyl group, or a lower alkoxycarbonyl group)], as well as to a medicine containing the derivative or salt as the active ingredient. The compounds exhibit strong binding inhibitory activity against endothelin having potent vasoconstrictive effect. Therefore, the compounds are effective as remedies for various diseases including circulatory diseases.
The invention relates to a chicken-derived antibacterial peptide. The sequence of the antibacterial peptide is as follows: &lt;xnotran&gt; MHCLKIMAFLLFFSLLLSQVYCASLHQPQP LLRLKRMTPFWRGVSLRPVGASCRKNSKCITMLCRKNRCFLRTASE, SEQ ID NO:1. &lt;/xnotran&gt; The improved chicken antibacterial peptide LEAP-2 contains 76 amino acid residues, has the molecular weight of 8847.8Da, the isoelectric point of 10.61, the positive charge of 13, the instability coefficient of 48.95 and the total average hydrophobicity of 0.195. The preparation method of the improved chicken-derived antibacterial peptide LEAP-2 comprises the following steps: constructing a prokaryotic expression vector pET28a, transforming BL21, inducing expression and purifying protein. The chicken-derived antibacterial peptide can be more efficiently expressed, has broad-spectrum antibacterial property, and compared with the original chicken-derived antibacterial peptide LEAP-2, the improved chicken-derived antibacterial peptide LEAP-2 has high antibacterial activity which is remarkably abnormal and stable and is not easy to inactivate. The chicken-derived antibacterial peptide has the instability coefficient of 48.95, and compared with the original chicken-derived antibacterial peptide, the stability is improved by 11.4 percent.
Background: Excitotoxicity, which is associated with the excessive activation of NMDA receptors, has been implicated as playing an important role in the progressive neuronal damage in.Alzheimer&#39;s disease (AD). Memantine, an open-channel blocker of NMDA receptors, is being used clinically to prevent the excitotoxicity. However, excitotoxicity is not the only process in which NMDA receptors can be dysregulated in AD. Recent studies have demonstrated that Aβ targets excitatory synapses, down regulates the surface expression of NMDA receptors, and induces reversible synaptic loss through NMDA receptor dependent pathways. To effectively treat Alzheimer&#39;s disease, a new therapeutic approach, which not only reduces the exitotoxicity but also potentiates normal NMDA receptor functions, needs to be explored. Objective: Given the fact that PKC activation potentiates functions of NMDA receptors, we aim to determine effects of the combination of a PKC activator, bryostatin-1, and memantine on the excitotoxicity and synaptic function. Methods: We used a biotinylation method and cell viability assays to determine the surface expression of NMDA receptors and the excitotoxicity of hippocampal neurons with or without the presence of bryostatin-1 and/or memantine. Results: We demonstrated that bryostatin-1 significantly enhanced the surface expression of NMDA receptors in hippocampal neurons. Treatment with the combination of bryostatin-1 together with memantine did not increase the excitotoxicity. On the contrary, it was more effective than either bryostatine-1 or memantine alone in the prevention of neuronal death caused by Aβ, regardless of the synaptic or extrasynaptic origin of the excitotoxicity. Conclusion: This study demonstrates that the combination of bryostatin-1 with memantine has potential as a new therapeutic approach for the effective treatment of Alzheimer&#39;s disease.
PURPOSE:To obtain a hair growth agent, capable of promoting hair growth regardless of symptoms or physical constitution and effective against various alopecias. CONSTITUTION:A hair growth agent is obtained by blending a phthalazinone derivative or 2,3-dihydroimidazo[2,1-a]phthalazinone derivative expressed by formula I or II (R&lt;1&gt; is straight-chain or branched chain hydrocarbon group; R&lt;3&gt; is H or alkyl), e.g. 4-butyl-1(2H)phthalazinone expressed by formula III as an essential ingredient in an amount of normally 0.001-20wt.%, preferably 0.10-10wt.% (0.01-10wt.% when the dosage form of the hair growth agent is a liquid such as a suspension or a paste such as an ointment) in the total composition of the hair growth agent with other ingredients. The resultant hair growth agent has excellent hair growth effects and is capable of promoting the hair growth in applied sites in its application to the scalp, etc. Furthermore, the hair growth gent is used as a medicine for external use and the dosage form is not especially limited. The dosage form is preferably a liniment such as an ointment, a lotion, a tonic, a spray, a suspension or an emulsion.
Doxorubicin (Dox) is widely used for breast cancer treatment but causes serious side- effects including cardiotoxicity that may adversely impact patient lifespan even if treatment is successful. The present invention relates to selective conjugation of Dox to a single site in a DNA hairpin resulting in a highly stable complex that enables Dos to be used more effectively. Selective conjugation of Dox to G15 in the hairpin loop was verified using site-specific labeling with [2- 15N3-2&#39;-deoxyguanosme in conjunction with [1 H-15NJ 2D NM R while 1:1 stoichiometry for the conjugate was validated by ESI-QTOF mass spectrometry and UV spectroscopy. Molecular modeling indicated covalently bound Dox also intercalated into the stem of the hairpin and stability studies demonstrated the resulting Dox-conjugated hairpin (DCH) complex had a half-life &gt; 30 h, considerably longer than alternative covalent and non- covalent complexes. Secondary conjugation of DCH with folic acid (FA) resulted in increased internalization into breast cancer cells. The dual conjugate, DCH-FA, can be used tor safer and more effective chemotherapy with Dox and this conjugation strategy can be expanded to include additional anti-cancer drugs.
FIELD: medicine. ^ SUBSTANCE: invention is referred to pharmaceutical industry, namely - to the extraction for production of composition for prevention, management or treatment of a neurologic disease, condition, dysfunction or disorder. Use of extraction of microalgae Aphanizomenom Flos Aquae Aquae Ralfs ex Born. &amp; Flax. Var. flos algae (AFA Klamath algae) for production of composition for prevention, management or treatment of a neurologic disease, condition, dysfunction or disorder chosen from: Alzheimer disease, Parkinson disease, multiple sclerosis, Attention deficit hyperactivity disorder (ADHD), autism, depression, memory deficiency and affective disorders where the extraction is produced using different stages. ^ EFFECT: prevention, management or treatment of a neurologic disease, condition, dysfunction or disorder. ^ 3 cl, 24 dwg, 3 tbl
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing a hybrid protein, and a pharmaceutical composition consisting of the hybrid protein.  &lt;P&gt;SOLUTION: This hybrid protein contains 2 co-expression amino acid sequences for forming a dimer. Each of the sequences contains a linking portion of a receptor such as TBP1 or TBP2, or a ligand such as IL-6, IFN-β and TPO linked with a hetero dimeric proteinous hormone subunit such as hCG. Each of co-expressing sequences contains a hormone subunit corresponding to the formation of the hetero dimer on its expression. The corresponding DNA molecule, expression vector and host cell, and a method for producing the protein and the pharmaceutical composition are also provided.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PURPOSE:To obtain the titled pharmaceutical, obtained by adding an alcohol, glycerol and fat or oil, etc. to a phospholipid fraction extracted from an egg yolk, and enveloping the resultant mixture in gelatin capsules, and having a high phospholipid concentration. CONSTITUTION:An egg yolk phospholipid pharmaceutical obtained by adding one or several kinds of additives consisting of an alcohol, glycerol and fat or oil to a phospholipid fraction extracted from an egge yolk, and enveloping the resultant mixture in gelatin capsules. The encapsulated egg yolk phospholipid pharmaceutical has been used regularly as nutriments or health food in recent years, but the phospholipid concentration is generally about 30%. The filling of a liquid material in soft capsules is almost impossible unless the viscosity of the liqiud material is about 2.0X10&lt;4&gt; cP or below. The use of the additives, e.g. the above- mentioned alcohol, permits the filling of the phospholipid fraction having about 45% concentration thereof in the phospholipid fraction and 2.0X10&lt;4&gt; cP or below viscosity.
PURPOSE:To obtain a hair cosmetic such as shampoo, hair rinse, hair conditioner and hair treatment giving excellent lasting softness to the hair by adding a beta-hydroxymonosulfonic acid or its salt and optionally further a surfactant to a hair cosmetic. CONSTITUTION:This hair cosmetic contains a beta-hydroxymonosulfonic acid of the formula (R&lt;1&gt; is H or 1-3C alkyl; X is H, metal atom or onium; R&lt;1&gt; and X are not H at the same time) or its salt. The compound of the formula is e.g. isethionic acid salt or 2-hydroxypropanesulfonic acid salt. These compounds may be used singly or a combination of two or more compounds and the amount of the compound in the total composition is 0.01-20wt.%. The hair cosmetic is preferably further compounded with a surfactant to improve the feeling in use or imparting detergent force to the agent. The surfactant is e.g. polyoxyethylene lauryl ether sulfuric acid sodium salt. The amount of the surfactant to be compounded to the total composition is 0.1-50wt.%.
The invention relates to an entacapone/folic acid compound medicine composition and application thereof and belongs to the technical field of pharmacy. The medicine composition contains officinal dose of entacapone, officinal dose of folic acid compound and a carrier acceptable in the pharmacy. The dose of the entacapone is 100-300mg, and the dose of the folic acid compound is 0.2-1.6mg. The entacapone/folic acid compound medicine composition has the advantages of strengthening curative effect on treatment of Parkinson&#39;s disease through multiple-target-point synergistic effect and improving the life quality of patients. The medicine composition still can effectively prevent and reduce the risk that Parkinson&#39;s disease patients are subjected to brain stroke through high homocysteine (Hcy) target points. In addition, the entacapone/folic acid compound medicine composition can be conveniently taken by the patients.
FIELD: medicine. SUBSTANCE: method involves applying combined treatment completed with measures for preventing and correcting injuries in the immune system by bringing to norm the general number of leukocytes and the number of lymphocytes in leukocyte formula as well as other parameters of general blood examination. Biostimulation agent is administered to patients beginning from minimum therapeutic dose 2-3 days before starting treatment and all over the whole course of any antitumor treatment daily before taking meals between 7 and 9 o&#39;clock. Each 2-3 days the dose is lowered for 30% when compared to the previous one. The second daily dose of the same biostimulation agent is to be added 5-8 days later after beginning the treatment course. The dose is to be given 2-2.5 h later after the first dose in the amount being 1.5-3 times as large as the first one. EFFECT: excluded immune depression and leukopenia. 2 tbl
PURPOSE:To obtain a deodorant readily water-soluble composition, containing an N-dibasic carboxylic acid monoacylated keratin peptide as a deodorizing base and having deodorizing effects on smell of both amines and mercapto groups with high safety without irritancy. CONSTITUTION:A deodorant composition containing a compound expressed by the formula (A is 2-6C hydrocarbon skeleton; R is amino acid side chain constituting keratin peptide; M1 and M2 are H, Na, K, etc.; n is 2-30) as a base. The cystine content in the keratin peptide is preferably high for deodorizing mercapto smell. A compound containing cystine in an amount of &gt;=6.0mol% expressed in terms of half cystine in amino acids constituting the keratin peptide is preferred in the compound expressed by the formula. The above-mentioned deodorant composition is readily usable even for deodorizing hair after permanent waving treatment without anxiety.
An apparatus, method, and system for the design, administration and implementation of a lifestyle management program. The lifestyle management system maximizes contact and enrollment rates of traditional lifestyle management. This is accomplished through the creation of a system that combines telephonic-delivered lifestyle management (i.e. traditional lifestyle management) with work-site based health center clinician (“trusted clinician”). The lifestyle management program is characterized by the involvement of a trusted clinician who actively participates in the program by being involved in the stratification process, the contact step and the process of creating and updating the patient&#39;s individualized care plan. Therefore, the lifestyle management program allows the clinician to be involved in both contact and enrollment phases of the program. The lifestyle management program further increases the efficiency of the program by improving overall health through behavior modification. The benefit of such a program is the reduction of health risk by effectively changing lifestyle behaviors which, in turn, allows employers administering the program to realize higher returns on their investment into such programs.
PURPOSE: To obtain the subject compd. in a good yield by an one-pot process cyclizing an aminoacrylic acid ester derived from an acid halide under heating and reacting the obtained by cyclic compd. with a heterocyclic compd. to obtain a 3-quinolonecarboxylic acid deriv. and neutralizing this deriv. to precipitate the same.  
     CONSTITUTION: An acid halide represented by formula I (wherein X 1  is H, a halogen, NH 2  or CH 3 ; Hal, X 2  and X 3  are each F or Cl; and A is CH, CF, CCl, C-OCH 3  or C-CH 3 ) and a dimethylaminoacrylic acid ester represented by the formula; (CH 3 ) 2 N-CH=CH-COOR (wherein R is a 1-3C alkyl or the like) are reacted to obtain a reaction product which is, in turn, reacted with an amino represented by the formula; R 1 NH 2  to obtain a compd. represented by formula II or the compd. represented by the formula I is reacted with an aminoacrylic acid ester represented by the formula; R 1 NH-CH=CH-COOR to directly obtain the compd. represented by the formula II. Subsequently, the obtained compd. is heated in the presence of a base and cyclized to obtain a compd. represented by formula III. Next, a compd. represented by formula IV (wherein R&#39; and R&#34; form a monocyclic or dicyclic heterocycle) is reacted with this compd. to obtain an ester represented by formula V and this ester is hydrolyzed to be neutralized to obtain a compd. represented by formula VI as a precipitate. This compd. is useful as a strong antibacterial agent. 
     COPYRIGHT: (C)1995,JPO
Interactive medication data systems and methods are provided which include automated means for providing information pursuant to telephonic and electronic requests from callers. The system includes a database containing information for patients and a variety of medications, a host system database containing prescription data for these medications, and means for receiving an incoming audio communication relating to a request for information concerning a specific medication. The audio communication contains a unique personal identifier which can be mapped to one patient in the host system database. The system then prompts the caller with a menu of selections relating to the patient&#39;s active prescriptions, such as, refill or dosage requirements. The caller then selects an option which produces a selection signal. The selection signal guides the system to look for specific data in the database and the system produces an audio or visual response to the caller.
The present invention provides an antioxidative composition with high safety, which is capable of lessening oxidative stress due to active oxygen species, free radicals, or the like in vivo, thereby preventing the occurrence or worsening of a disease. &lt;??&gt;It was confirmed that by using a composition containing oxidized coenzyme Q and/or reduced coenzyme Q, the amount of urinary 8-hydroxydeoxyquanosine can be decreased in normal or diabetic animals. Also, in histopathological research of the spleens of diabetic rats, it was confirmed that spleen tissue denaturation caused by oxidative stress can be prevented. It was thus found that oxidative stress in vivo can be lessened. &lt;??&gt;According to the present invention, oxidative stress in vivo can be lessened by using a composition containing coenzyme Q as an active ingredient.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition for promoting early healing of bone fracture.  &lt;P&gt;SOLUTION: There is provided the composition for promoting healing of bone fracture comprising a PDE4 inhibitor as an active ingredient, which has a phosphodiesterase (PDE) 4 inhibiting function. Specifically, a composition having a PDE4 inhibitor and a biocompatible and biodegradable polymer (for example, a polyester of a hydroxy fatty acid such as lactic acid, etc.) is provided, which composition, when formulated into a form suitable for local administration such as a microsphere preparation. The composition is useful in, for example, healing of refractory fracture of elderly people and diabetic or osteoporosis patients.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The disclosure relates to systems, methods, and devices for monitoring a patient&#39;s blood and cardiac condition. Patients with diabetes oftentimes wear diabetes management equipment (e.g., a glucose monitor, an external insulin pump, or a device having dual functionality). Such patients risk silent myocardial infarction. Herein described is regular cardiac ischemia/infarction monitoring—which if not monitored can lead to (silent) myocardial infarction. Moreover herein described are combined blood monitoring functionality and cardiac condition monitoring functionality via a single device, meaning that the patient is not required to wear additional equipment. Adding this functionality to already-existing equipment is significantly less invasive than requiring a patient to wear one piece of equipment to monitor his/her blood and a second piece of equipment to monitor his/her cardiac condition. This reduction in invasiveness can lead to significantly greater patient participation and compliance, which can improve health and save the lives of many patients.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a functional food product having functions of lowering serum lipid, blood pressure and blood sugar while reducing accumulated fat tissues.  &lt;P&gt;SOLUTION: Ion exchange water of 50 l is added to the entire herb of Glechoma hederacea of 5 kg, and it is heated at 90°C and extracted for 1 hr. After the extraction, solid/liquid separation by pressing is carried out to obtain an extract. The extract is vacuum-concentrated, thereafter freeze-drying is carried out to obtain a dried material. The died material is powdered by a crusher (Wonder Blender WB-1, Osaka Chemical) to obtain an extract of Glechoma hederacea of 1 kg through a 100 meshe sieve, additionally.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The invention relates to acrylate polymers comprising a K-value ranging from 10 to 60, which can be obtained by the radical polymerization of: 30 to 99 wt.  % of tert-butyl acrylate and/or tert-butyl methacrylate designated as monomer A; 1 to 28 wt. % of acrylic acid and/or methacrylic acid designated as monomer B, and; 0 to 60 wt. % of a radically copolymerizable monomer or of a radically copolymerizable monomer mixture designated as monomer C, whereby at least one of monomers C yields a homopolymer with a glass-transition temperature lower than 30 ~C, with the provision that the wt. %&#39;s total 100. The radical polymerization is carried out in the presence of alkane thiols with a C chain length of C 14 to C 22. The invention also relates to acrylate polymers comprising a K-value ranging from 10 to 60, which can be obtained by the radical polymerization of: 30 to 99 wt. % of tert-butyl acrylate and/or tert-butyl methacrylate designated as monomer A; 1 to 28 wt. % of acrylic acid and/or methacrylic acid designated as monomer B, and; 0 to 60 wt. % of a radically copolymerizable monomer or of a radically copolymerizable monomer mixture designated as monomer C, whereby at least one of monomers C yields a homopolymer with a glass-transition temperature lower than 30 ~C, with the provision that the wt. %&#39;s total 100. The radical polymerization is carried out in the presence of alkane thiols with a C chain length of C 10 to C 22 followed by a hydrogen peroxide treatment. The invention also relates to the use of these acrylate polymers as film formers as well as to their use in cosmetic preparations.
PURPOSE:To provide the titled mica having excellent color tone such as brightness, chroma, etc., and desirable surface color and interference color, and suitable for paint, ink, cosmetics, etc., by coating the surface of mica with titanium oxide nitride or a titanium compound, and further coating the coated surface with titanium dioxide. CONSTITUTION:The objective mica can be prepared by coating (A) the surface of mica with (B) preferably 0.01-60pts.wt. (based on 100pts.wt. of mica) of titanium oxide nitride or a titanium compound containing titanium oxide nitride at a thickness of &gt;=200Angstrom , and further coating the surface with (C) titanium dioxide at a thickness of e.g. 50-5,000Angstrom . EFFECT:Excellent pigment properties such as stability, safety, acid resistance, solvent resistance, etc., and excellent electrical conductivity characteristics such as specific resistance, etc.